Akron Children's Hospital > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Omaveloxolone for patients with mitochondrial myopathy

Omaveloxolone (RTA 408) for patients with mitochondrial myopathy

Description:

This study is closed.

For more information on this study, visit: https://clinicaltrials.gov/ct2/show/NCT02255422

Who May Qualify?:

Male or female mitochondrial myopathy patients 18 through 75 years of age.

We will screen potential study participants for additional criteria.

Who Does Not Qualify:

For detailed information on qualifying for enrollment visit: https://clinicaltrials.gov/ct2/show/NCT02255422

Study Status:

Closed

Study Sponsor:

Reata Pharmaceuticals, Inc.

Full IRB Study Title:

A Phase 2 Study of the Safety, Efficacy and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy

IRB Study ID:

408-C-1403

If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-5012

Lead Investigator

Bruce H. Cohen, MD, FAAN

Chair, NeuroDevelopmental Science Center; Philip H. Maynard Chair in NeuroDevelopmental Science Fund; Chairman, American Academy of Neurology Advocacy Committee; Pediatric Neurologist
Pediatric Brain Tumor ProgramPediatric NeurologyMitochondrial Center

While we are ranked among the best children's hospitals in the country, it's our compassionate approach to treatment that makes us truly exceptional. Through a combination of revolutionary treatments and extraordinary patient experiences, our care does more than heal. It brings the entire family together for emotional support and understanding across multiple locations to reach you in the community where you live. Learn more...